A Novel Stop-Gain Mutation in *MSH2* Gene Among a Persian Family Fulfilling Classic Amsterdam Criteria for Lynch Syndrome

Paniz Miar

Isfahan University of Medical Sciences

Sina Narrei

Isfahan University of Medical Sciences

Mohammad Amin Tabatabaiefar

Isfahan University of Medical Sciences

Mohammad Reza Pourreza

Isfahan University of Medical Sciences

Morteza Hashemzadeh-Chaleshtori

Cellular and Molecular Research Center <https://orcid.org/0000-0003-1381-0582>

Mohammad Hassan Emami

Isfahan University of Medical Sciences

Mehrdad Zeinalian (✉ m.zeinalian@med.mui.ac.ir)

Isfahan University of Medical Sciences

Research Article

Keywords: novel mutation, MSH2 gene, Persian, Amsterdam criteria, Lynch syndrome

Posted Date: February 22nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-158152/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Purpose

Lynch syndrome is the most common hereditary cancer syndromes due to a germline mutation in one of the mismatch-repair (MMR) genes. It results in early-onset colorectal cancer (CRC) and other Lynch-associated cancers in an autosomal dominant pattern. In this article, a new pathogenic variant in a Persian family with familial CRCs and positive Amsterdam II criteria has been described.

Methods

IHC-MMRs was done on tissue sections from tumor and its adjacent healthy tissue of the proband. Microsatellite instability (MSI) testing was also performed on DNA extracted from tumor and healthy tissue using Promega kit. Next Generation Sequencing (NGS) was finally done on genomic DNA of the proband using a 12-gene-panel including MMR genes. Variant filtering and prioritization were done using bioinformatics tools. Co-segregation analysis was used to evaluate the explored pathogenic variant.

Results

The proband was a 38-year woman at-diagnosis affected with CRC located in the sigmoid colon. The family history of cancer was observed in three successive generations. IHC was absent for MSH2 and MSH6, and MSI-High was reported from MSI testing. NGS analysis explored a new stop gained codon mutation on the first exon of *MSH2* gene as a substitution of A to G *MSH2*: c.364A > T which was pathogenic according to the variant interpretation guidelines of American College of Medical Genetics and Genomics.

Conclusion

Revealing of a more obvious molecular feature of Lynch-syndrome among Iranian populations could lead to identification of at-risk people for early care and prevention of cancer.

Introduction

Colorectal cancer (CRC) is one of the most common cancers throughout the world which its prevalence is rapidly increasing among the developing countries as Iran, likely due to the westernization of general life style[1]. CRC is now second and fourth common cancer among Iranian women and men, respectively. Nevertheless, no systematic program has been set up so far for general screening and early detection of this common healthcare problem in Iran (2–4).

Lynch syndrome (LS), the most common hereditary cancer predisposing syndrome, accounts for 3–5% of the CRC patients. It is an autosomal dominant disorder in which the lifetime cancer risk of carriers increases up to 80%, most of which occurs before 50 years ages [5, 6]. Although CRC and endometrial cancers include most of the LS-associated cancers, other organs such as stomach, small bowel, upper uroepithelial and, hepatobiliary tract, breast, ovary, brain, and even skin could be primarily involved in carriers [7–9]. Molecular pathogenesis of LS is germline mutation in at least one of the four DNA mismatch repair (MMR) genes including *MLH1*, *MSH2*, *PMS2*, and *MSH6*. Moreover, the germline deletion of 3' end of *EPCAM*, a gene located immediately upstream of *MSH2*, has been recently introduced as a cause of epigenetic silencing of *MSH2* leading to LS [10, 11]. MMR deficiency causes a characteristic molecular phenotype in which DNA microsatellites, short tandem repeats (STR) with 1–6 nucleotides repeating units, show instability. It is called, “Microsatellite Instability” (MSI) which is routinely used as a surrogate marker for MMR deficiency by a genetic test entitled: MSI testing [12, 13]. MMR deficiency could be also evaluated by immunohistochemical (IHC) staining of tumor sections with MMR proteins [14]. LS would be confirmed if at least a germline pathogenic variant is found in MMR genes. Otherwise, Lynch-like syndrome is suggested for the patient with MMR deficient tumor with no identified germline mutation in MMR genes [10, 15].

Although a few studies have been launched on epidemiological, clinicopathological and molecular aspects of CRC among Iranian populations, this limited data is suggestive for a different molecular feature of the disease in Iranian ethnicities compared to the populations of other countries [4, 16]. We report in this article a new pathogenic variant of *MSH2* gene which was found in a Persian family with LS.

Methods

Subjects and clinical samples

The subjects of this study include four members of a family with Amsterdam II criteria [17]. These criteria are usually used to screen at-risk families for LS including: Three or more affected members with histologically confirmed CRC or other LS-associated cancers such as endometrium, small intestine, stomach, urinary tract, skin, brain, and breast, one of whom being a first-degree relative of the other two; familial adenomatous polyposis should be excluded; two or more successive generations are affected, and at least one affected members was diagnosed before 50 years old. In our study, there were at least five cancer-affected members in three successive generations of the family of whom three patients were affected by CRC. (Fig. 1)

The index case was a 40-year-old woman (38 years at diagnosis) whose tumor was located in sigmoid.

We used genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue for MSI testing and IHC staining. The genomic DNA extracted from peripheral blood was also used for the targeted Next Generation Sequencing (NGS).

Molecular Studies

MSI testing and IHC staining of MMR proteins were simultaneously used to screen the proband at risk for Lynch syndrome.

Microsatellite Instability testing

A commercial kit from Promega (MSI Analysis System, Version 1.2) was used for MSI testing including five standard quasimonomorphic markers to detect MSI and two pentanucleotide markers to identify tissue mix up. The amplified DNA products of a multiplex fluorescent PCR on extracted DNA of both tumor and healthy tissue were analyzed in a fragment analysis process using Applied Biosystems 3130 Genetic Analyzer. Comparison of obtained signals for each marker in a tumor tissue with its adjacent normal tissue was applied to explore MSI. Therefore, observing instability in at least two of the five mononucleotide microsatellite markers, MSI-H (high) confirmed MMR deficient status.

Immunohistochemistry

MMR proteins (MLH1, MSH2, PMS2, and MSH6) were used as mouse monoclonal primary antibodies in IHC staining (Leica Biosystems: Novocastra, UK).

A FFPE tissue block was used from resected bowel specimen included tumoral and adjacent healthy mucosa. At least four slides were provided to evaluate four MMR proteins. The incubation with Protein Block reagent, primary antibodies, and post-primary block reagent was done, respectively, according to IHC guideline specific for each immunologic product. The slides should be washed for a short moment in each step using TBS with gentle rocking. Then the induction of peroxidase activity was done with DAB working solution for some minutes. Counterstaining of the slides with Hematoxylin and finally dehydrating, clearing and mounting of them were the last step before microscopic observation. Since MMR genes are located in the nucleus, nuclear staining would be absent in the MMR deficiency. Due to the association of PMS2 and MSH6 proteins (accessory MMR proteins) to MLH1 and MSH2 proteins (main MMR proteins), IHC absence of MLH1 could indicate deficiency in each of MLH1 and PMS2 proteins. While IHC absence of PMS2, MSH2, and MSH6 would only indicate deficiency in the related proteins.

Next Generation DNA Sequencing

After initial sample quality control (QC) according to Illumina's library guideline [18], Otogenetics (Norcross, GA, USA) CRC targeted panel (Oto-ColoCa) that approximately captures 30kbp DNA involving 11 genes (*APC*, *MLH1*, *MSH2*, *MSH6*, *TP53*, *CDKN2A*, *PTEN*, *MUTYH*, *BMPR1A*, *SMAD4* and *STK11*) was performed followed NGS using the HiSeq2000 (Illumina, USA) platform. Enriched DNA was sequenced using a 2*100 bp, paired-end read strategy and average on-target coverage was 100x.

Bioinformatics analysis

The raw sequencing reads obtained from NGS were filtered to remove the low-quality reads with more than 10% of uncalled bases, appending the N bases at the end of reads, and removing every chimera with more than 15 bases matched to the primer sequences. Then the qualified reads were mapped to human genome (hg19) by BWA v0.7.12 [19]. Moreover, the single nucleotide variants (SNVs) and short insertions/deletions (indels) were called using Genome Analysis Toolkit (GATK v 3.4–46)[20]. The filtration of SNVs and indels was performed according to the GATK best practice pipeline. For confirmation of that all of the intended genes have been captured by NGS, the Integrative Genomics Viewer (IGV 2.6x) was used for analysis of BAM files. Variant annotation regarding to the functional effects was fulfilled by ANNOVAR and snpEff software [21, 22]. All of the variant filtered against the Minor Allele Frequency (MAF) of 1% to rule out the potential polymorphisms according to the annotation that were based on the 1000 Genome [23], The Genome Aggregation Database (gnomAD) [24], and The Exome Aggregation Consortium (ExAC) population databases [25]. Homozygous variants were also excluded because the inheritance pattern of the lynch syndrome is dominant. Since the loss of function (LOF) of the genes is the main reason of the hereditary cancer like LS [26], our investigation in the variants started from those variants (frameshifts, stop codon, initiation codon, and critical splice site regions) resulting in the null proteins. The prediction of splice site variants was made with Human Splicing Finder [27]. Further investigations, if needed, are preceded with missense variants using computational tools including mutation taster [28], mutation assessor [29], SIFT [30], and polyphen-2 [31] for determining the damaging probability of them. Finally, the identified variants pathogenicity can be interpreted according to ACMG 2015 standards and guidelines for the interpretation of sequence variants [32].

Co-segregation Analysis by PCR-Sanger Sequencing

Rather than the proband, her three first degree members were also investigated for the existence of the identified pathogenic variant. They include her father, as an affected member with CRC, and two her healthy sisters. Co-segregation analysis was carried out by PCR-Sanger sequencing of genomic DNA extracted from peripheral blood of the cases. The forward (GCATGAAGTCCAGCTAATACAG) and reverse (GCTATTAAAGTGTCTCAAACCA) primers were designed to amplify the DNA fragment that included the identified variant. The PCR program was set up as 95°C for 5 min (1 cycle), 94°C for 30 s, 58°C for 30 s, and 72°C for 20 s (30 cycles), and the final extension at 72°C for 1 min. The PCR products were analyzed in 2% gel agarose electrophoresis. After PCR reaction, the amplicon was run on 2 % agarose gel to confirm the size 357 bp. Sanger sequencing was done by Applied Biosystems 3130xl Genetic Analyzer, 16-capillary electrophoresis.

Results

The under-studied family included at least five confirmed cancer patients within three successive generations: three colorectal cancers, one prostate, and one breast cancer. (Fig. 1)

The proband (III-3) was a 38-year woman at diagnosis affected with CRC located in the sigmoid colon. The pathologic diagnosis had been reported as, “well differentiated adenocarcinoma” in B stage

according to the modified Astler-Coller classification about three months after onset of clinical symptoms in Nov 2010, including chronic constipation and hematochezia. The proband's father (II-4) had been also affected by CRC in rectosigmoid colon in 66 years old, two years before her daughter.

In MSI testing and IHC staining of MMR proteins on colorectal tumor and normal tissue of the proband, MSI-H and IHC-MMR absent phenotype in both MSH2 and MSH6 proteins were concluded. Totally 16,482 variants have been called, and analysis of them proceeded according to method that we have described. Altogether, one null and six synonymous and missense variants have been identified. Figure 2

Finally, a heterozygous clinically significant variant was identified in *MSH2* gene that a substitution of A to T results in a stop codon on the first exon of the gene transcript (*MSH2* (NM_000251.2): c.364A > T, rs374127044) and the variant was not found neither in any population nor the disease databases like ClinVar and OMIM.

In co-segregation analysis, altogether two affected and two unaffected members of the pedigree were assessed to evaluate c.364A > T variant in *MSH2* gene by PCR-Sanger Sequencing. This variant was found in both affected members (II4 and III3) and also one of the two healthy sisters of the proband (III4). Figure 3

Discussion

In the present study, a familial cancer pedigree with Persian origin was ascertained. Three of five cancer patients were affected by CRC. Two other cancer patients had breast or prostate cancers. We were able to identify the molecular etiology taking advantage of NGS technology.

Based on a literature review of clinicopathologic studies, *MSH2* germ-line mutations present more extracolonic malignancies in comparison to other MMR genes [33, 34]. Although breast and prostate cancers have not considered as Lynch-associated cancers in some studies, there are some lines of evidence suggesting that MMR deficiency could increase the incidence of these cancers in MMR deficient carriers (24–27). We have recently evaluated breast and prostate cancers as the first and the third frequent extracolonic cancers among Iranian MMR deficient families in a case series study [39].

According to IHC-MMR results on the tumor FFPE tissue of the proband, both MSH2 and MSH6 proteins were suggested to be defective. Therefore, we expected a pathogenic variant to be found in *MSH2* gene through NGS identified variant analysis. MSH2 is one of the main MMR protein in which the accessory protein is MSH6. According to the Human Gene Mutation Database[40], a valid well-known database within human genes and mutations, by Jun 30, 2019, altogether 1008 pathogenic variants had been registered for *MSH2* gene of which 32.9% were missense/nonsense variants (Fig. 4) (35). The identified heterozygous variant (*MSH2* (NM_000251.2): c.364A > T, rs374127044) was located in the first exon of *MSH2* gene results in a stop codon. It is the only identified pathogenic variant that compatible with IHC-MMR findings. Given the type of the variant (null allele) and simultaneous defect of both MSH2 and MSH6 proteins in IHC staining, this variant is most likely responsible for MMR deficient phenotype in the

family. On the other hand, according to the ACMG 2015 guidelines and standards for interpretation of sequence variants [32], the identified variant matches with the criteria for categorizing as pathogenic for cause of lynch syndrome. The variant was nonsense, and it could result in the loss of function of *MSH6* gene product, matches with the mechanism of LS, a very strong evidence for pathogenicity (PVS1) [26]. Moreover, this variant has not been found in any population databases including 1000 genome, ExAC, and gnomAD in which give a moderate evidence for being pathogenic. The variant was also found in both affected CRC patients in the family, while one of the first-degree healthy members of the proband did not present this variant in co-segregation analysis. (Fig. 3) Altogether, the presence of a null variant, absence of being in population data bases, a positive family history of multiple cancers related to LS, especially in the phenotypic feature of the proband, and the presence of the variant in both affected CRC patients in the family are enough to satisfy us for categorizing of the variant as pathogenic.

Conclusion

Molecular analysis of a Persian family with clinical AC II and a history of five cancer patients within three successive generations explored a new stop gained codon mutation on the first exon of *MSH2* gene as a substitution of A to G *MSH2* (NM_000251.2): c.364A > T, rs374127044). Given the lack of enough molecular and clinicopathologic information about LS affected families among Iranian populations, more evaluations are recommended to explore other pathogenic variants of MMR genes among Iranian LS families and more comprehensive *in vitro* studies should be considered based on the identified variant in this study.

Declarations

Funding: This article has been concluded of a PhD project supported by *Shahrekord University of Medical Sciences*.

Conflicts of interest/Competing interests: The authors declare no conflicts/competing interests.

Availability of data and material: All data related to the results are available in the data repository of the PI.

Code availability: Not applicable

Ethics approval: This study has been ethically approved by research deputy of *Shahrekord University of Medical Sciences*.

References

1. Samadder NJ, Curtin K, Wong J, et al (2014) Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 12:2078–84.e1–2. <https://doi.org/10.1016/j.cgh.2014.04.017>.

2. Azadeh S, Moghimi-Dehkordi B, Fatem SR, et al. Colorectal cancer in Iran: an epidemiological study. *Asian Pac J Cancer Prev APJCP*. 2008;9:123–6.
3. Molaei M, Mansoori BK, Ghiasi S, et al. Colorectal cancer in Iran: immunohistochemical profiles of four mismatch repair proteins. *Int J Colorectal Dis*. 2010;25:63–9. <https://doi.org/10.1007/s00384-009-0784-1>.
4. Dolatkhah R, Somi MH, Bonyadi MJ, et al. Colorectal cancer in iran: molecular epidemiology and screening strategies. *J Cancer Epidemiol*. 2015;2015:643020. <https://doi.org/10.1155/2015/643020>.
5. Boland CR, Lynch HT. The history of Lynch syndrome. *Fam Cancer*. 2013;12:145–57. <https://doi.org/10.1007/s10689-013-9637-8>.
6. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin Genet*. 2009;76:1–18. <https://doi.org/10.1111/j.1399-0004.2009.01230.x>.
7. Lynch HT, Riegert-Johnson DL, Snyder C, et al. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. *Am J Gastroenterol*. 2011;106:1829–36. <https://doi.org/10.1038/ajg.2011.203>.
8. Maul JS, Warner NR, Kuwada SK, et al. Extracolonic cancers associated with hereditary nonpolyposis colorectal cancer in the Utah Population Database. *Am J Gastroenterol*. 2006;101:1591–6. <https://doi.org/10.1111/j.1572-0241.2006.00636.x>.
9. Bansidhar BJ. Extracolonic manifestations of lynch syndrome. *Clin Colon Rectal Surg*. 2012;25:103–10. <https://doi.org/10.1055/s-0032-1313781>.
10. Kang SY, Park CK, Chang DK, et al. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers. *Int J Cancer*. 2015;136:1568–78. <https://doi.org/10.1002/ijc.29133>.
11. Kempers MJE, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol*. 2011;12:49–55. [https://doi.org/10.1016/S1470-2045\(10\)70265-5](https://doi.org/10.1016/S1470-2045(10)70265-5).
12. Kim NK. Is a Microsatellite Instability Still Useful for Tailored Treatment in Stage II and III Colon Cancer? *Ann Coloproctology*. 2014;30:5–6. <https://doi.org/10.3393/ac.2014.30.1.5>.
13. Vilar E, Mork ME, Cuddy A, et al. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. *Cancer Genet*. 2014;207:495–502. <https://doi.org/10.1016/j.cancergen.2014.10.002>.
14. Amira AT, Mouna T, Ahlem B, et al. Immunohistochemical expression pattern of MMR protein can specifically identify patients with colorectal cancer microsatellite instability. *Tumour Biol J Int Soc Oncodevelopmental Biol Med*. 2014;35:6283–91. <https://doi.org/10.1007/s13277-014-1831-2>.
15. Carethers JM. Differentiating Lynch-like from Lynch syndrome. *Gastroenterology*. 2014;146:602–4. <https://doi.org/10.1053/j.gastro.2014.01.041>.
16. Zeinalian M, Emami MH, Salehi R, et al. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature. *J Gastrointest Cancer*. 2015;46:118–25. <https://doi.org/10.1007/s12029-015-9696-1>.

17. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology*. 1999;116:1453–6. [https://doi.org/10.1016/s0016-5085\(99\)70510-x](https://doi.org/10.1016/s0016-5085(99)70510-x).
18. CEES D of MGUK 166NO-0407 ON NSC - Sequencing. <https://www.sequencing.uio.no/index.html>. Accessed 9 Aug 2019.
19. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinforma Oxf Engl*. 2010;26:589–95. <https://doi.org/10.1093/bioinformatics/btp698>.
20. Van der Auwera GA, Carneiro MO, Hartl C, et al (2013) From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinforma* 43:11.10.1–33. <https://doi.org/10.1002/0471250953.bi1110s43>.
21. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010;38:e164. <https://doi.org/10.1093/nar/gkq603>.
22. Cingolani P, Platts A, Wang LL, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly*. 2012;6:80–92. <https://doi.org/10.4161/fly.19695>.
23. The 1000 Genomes Browsers. | 1000 Genomes. <https://www.internationalgenome.org/1000-genomes-browsers/>. Accessed 9 Aug 2019.
24. Clemens DJ, Lentino AR, Kapplinger JD, et al. Using the genome aggregation database, computational pathogenicity prediction tools, and patch clamp heterologous expression studies to demote previously published long QT syndrome type 1 mutations from pathogenic to benign. *Heart Rhythm*. 2018;15:555–61. <https://doi.org/10.1016/j.hrthm.2017.11.032>.
25. Das R, Ghosh SK. Genetic variants of the DNA repair genes from Exome Aggregation Consortium (EXAC) database: significance in cancer. *DNA Repair*. 2017;52:92–102. <https://doi.org/10.1016/j.dnarep.2017.02.013>.
26. Cohen SA, Leininger A. The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. *Appl Clin Genet*. 2014;7:147–58. <https://doi.org/10.2147/TACG.S51483>.
27. Human Splicing Finder. - Version 3.1. <http://www.umd.be/HSF/index.html>. Accessed 10 Aug 2019.
28. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods*. 2014;11:361–2. <https://doi.org/10.1038/nmeth.2890>.
29. Reva B, Antipin Y, Sander C. Determinants of protein function revealed by combinatorial entropy optimization. *Genome Biol*. 2007;8:R232. <https://doi.org/10.1186/gb-2007-8-11-r232>.
30. Sim N-L, Kumar P, Hu J, et al. SIFT web server: predicting effects of amino acid substitutions on proteins. *Nucleic Acids Res*. 2012;40:W452–7. <https://doi.org/10.1093/nar/gks539>.
31. Adzhubei I, Jordan DM, Sunyaev SR. (2013) Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet Chap 7:Unit7.20*. <https://doi.org/10.1002/0471142905.hg0720s76>.

32. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med Off J Am Coll Med Genet*. 2015;17:405–24. <https://doi.org/10.1038/gim.2015.30>.
33. Kastrinos F, Steyerberg EW, Balmaña J, et al. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. *Gut*. 2013;62:272–9. <https://doi.org/10.1136/gutjnl-2011-301265>.
34. Pérez-Cabornero L, Infante M, Velasco E, et al. Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome. *Int J Colorectal Dis*. 2013;28:1195–201. <https://doi.org/10.1007/s00384-013-1685-x>.
35. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 2014;23:437–49. <https://doi.org/10.1158/1055-9965.EPI-13-1165>.
36. Raymond VM, Mukherjee B, Wang F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. *J Clin Oncol Off J Am Soc Clin Oncol*. 2013;31:1713–8. <https://doi.org/10.1200/JCO.2012.44.1238>.
37. Lotsari JE, Gylling A, Abdel-Rahman WM, et al. Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. *Breast Cancer Res BCR*. 2012;14:R90. <https://doi.org/10.1186/bcr3205>.
38. Haraldsdottir S, Hampel H, Wei L, et al. Prostate cancer incidence in males with Lynch syndrome. *Genet Med Off J Am Coll Med Genet*. 2014;16:553–7. <https://doi.org/10.1038/gim.2013.193>.
39. Zeinalian M, Hashemzadeh-Chaleshtori M, Akbarpour MJ, Emami MH. Epidemioclinical Feature of Early-Onset Colorectal Cancer at-Risk for Lynch Syndrome in Central Iran. *Asian Pac J Cancer Prev APJCP*. 2015;16:4647–52. <https://doi.org/10.7314/apjcp.2015.16.11.4647>.
40. HGMD®. home page. <http://www.hgmd.cf.ac.uk/ac/>. Accessed 11 Aug 2019.

Figures

Figure 1

The pedigree of a Persian family with familial cancer in three successive generations.

Figure 2

Variant analysis procedure: (A) Totally 16,482 variants have been called through the targeted exome sequencing of which 97% were not in exonic region and 3% were. (B) Out of them 17 % were heterozygous that compatible with the inheritance pattern of LS. (C) The heterozygous variants filtered based on the MAF of 1% and totally 6 synonymous/missense variants and 1 null variant have been identified. The final variant, MSH2:c.364A>T(p.Lys122Ter) was the disease causing based on the ACMG 2015 guideline for LS.

Figure 3

The electropherogram of DNA sequence illustrating of g.364A>T variant of MSH2 gene in two affected (II4 and III3) and one healthy members (III4) of the pedigree

Figure 4

The frequency distribution of all type mutations in the MSH2 gene according to “Human Gene Mutation Database” as of Jun18, 2021 (40)